Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

Clinical remission · Patients with active Crohn's disease

Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.26 [1.03, 1.54]
1 study · 338 participants
Moderate

Clinical remission off steroids · Patients with active Crohn's disease

Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.23 [1.02, 1.47]
2 studies · 383 participants
Moderate

Clinical remission · Patients with active Crohn's disease

Azathioprine probably leads to lower clinical remission compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.66 [0.51, 0.87]
1 study · 339 participants
Moderate

Clinical remission off steroids · Patients with active Crohn's disease

Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.68 [0.51, 0.9]
1 study · 339 participants
Moderate